



Marker genes for obesity and NASH progression

Kiel clinical expression study

Andreas Hoppe Institut für Biochemie Charité – Universitätsmedizin Berlin





Outline

- o Introduction
- o Obesity markers
- o Steatosis markers
- o Inflammation markers
- o Fibrosis markers
- o General disease markers




Outline

- o Introduction
- o Obesity markers
- Steatosis markers
- o Inflammation markers
- o Fibrosis markers
- o General disease markers



Kiel study

- o Hospital liver biopsies
 - liver disease patients
 - bariatric surgery candidates
- o Full-genome gene expression
- Detailed patient information
 - BMI (quant.)
 - liver fat % measure (quant.)
 - Ballooning cells (qual.)
 - Inflammation (qual.)
 - Fibrosis (qual.)
 - age, diabetes, gallstone, weight, height, bariatric surgery



Balloon cells




5 Dimensions

- o BMI (quant.)
- Steatosis (quant.)
 - fat % measure (quant.)
 - Ballooning cells (qual.)
- o Inflammation (qual.)
- o Fibrosis (qual.)
- NAFLD consensus (average of steatosis, inflammation, fibrosis)

Histograms of parameters







Intro — Obesity — Steatosis — Inflammation — Fibrosis — Disease



Aim

Gene expression correlated with obesity and NASH *FITHER*

- o involved in disease mechanism
 - part of causal chain

OR

- o consequence of disease
 - compensation
 - decompensation



Method

- o For each phenomenological parameter
 - obesity
 - steatosis, inflammation, fibrosis
 - NAFLD consensus
- o For each gene, compute
 - Correlation (r)
 - t-test (that non-zero correlation)
- o Genes with maximal correlation |r|
- Split metabolic and non-metabolic genes
- \rightarrow 10 ranked lists





| | steatosis | inflammation | fibrosis | disease |
|--------------------------------------|-----------|--------------|---|----------|
| obesity steatosis inflammation | | • | $\begin{array}{ccc} 0.15 & p{=}0.08 \\ 0.36 & p{<}1.2 \cdot 10^{-5} \\ 0.55 & p{<}2.4 \cdot 10^{-12} \end{array}$ | |
| fibrosis | | | • | 0.76 p=0 |



Outline


- o Introduction
- o Obesity markers
- Steatosis markers
- o Inflammation markers
- o Fibrosis markers
- o General disease markers

Obesity markers



| Gene | r | p< | rank non-metabolic | rank total | |
|--------|-------|----------------------|--------------------|------------|---|
| GRID1 | 0.66 | 0 | 1 | 1 | glutamate receptor, ionotropic, delta 1 |
| PRKCE | 0.58 | $4.4 \cdot 10^{-16}$ | 2 | 2 | protein kinase C, epsilon |
| GRM8 | 0.57 | $1.6 \cdot 10^{-15}$ | 3 | 3 | glutamate receptor, metabotropic 8 |
| RAMP1 | -0.57 | $2.2 \cdot 10^{-15}$ | 4 | 4 | receptor (G protein-coupled) activity modifying protein 1 |
| CAMK1D | 0.56 | $3.3 \cdot 10^{-15}$ | 5 | 5 | calcium/calmodulin-dependent protein kinase ID |
| STAB2 | 0.55 | 2.5.10-14 | 6 | 6 | stabilin 2 |

| Gene | ľ | p< | rank metabolic | rank total | |
|---------|-------|-----------------------|----------------|------------|--|
| HSD17B7 | 0.53 | 3.8-10-13 | 1 | 11 | hydroxysteroid (17-beta) dehydrogenase 7 |
| SQLE | 0.5 | $8.5 \cdot 10^{-12}$ | 2 | 21 | squalene epoxidase |
| SLC16A7 | -0.48 | 9.5-10-11 | 3 | 41 | solute carrier family 16 (monocarboxylete transporter), member 7 |
| COX7B | -0.47 | $3.3 \cdot 10^{-10}$ | 4 | 50 | |
| ABCB11 | -0.46 | $4.1 \cdot 10^{-10}$ | 5 | 56 | |
| CA13 | 0.46 | 6.3·10 ⁻¹⁰ | 6 | 61 | carbonic anhydrase XIII |





GRID1, Glutamate receptor δ 1 subunit Top obesity marker


| | | 10 00 | / | | | |
|-------------|-----------|----------|-------------------|-------------------------|-------------------------------|-----------|
| 7 | | I | | 0 | Φ | _ |
| · [| | | | 0 0 | | |
| | | | | ~0 | | |
| Γ | | 0 | | 00 | 0 | • |
| F | | | | ° ° | - | |
| | o | °O | 00 | _Ф О | 0 | 0 |
| 6 - 5 - 5 - | | · · | 000 | Ο. | ~ & ~ | _ |
| | | | | • | 6 8 | |
| . L | | 000 | 0 0 6 - | O 9 | , <u>&</u> O & | |
| | ٥ | a 0 ' | ° 6 0 | 0 | | |
| · | | ွဝ္ခ | 6 | 0 . | | |
| ٠ | °00 | ٥ | 800 | \wp° , \circ | | |
| 5 | 0 | • 0 | 8 , | in v | 0 | - |
| - | | <u> </u> | • 0 | ၀ိ၀္က ° | | |
| - | 0 🕳 0 | og 8 | O a | 0 0 | | |
| L | ం ్రిస్తి | ి ٥ | | | o no fat co | ntent |
| P | 0 | o | o o | | fat conte | nt 18% |
| . [| | • | O | • 0 | fat conte | nt 930% · |
| 4 | ್ಯ ಕಿ | | 0 | | O fat conte | nt>70% |
| | 0 0 | | | | | |
| | 20 | | 40 | | 60 | |
| | | | BM | II | | |

| Factor | r | p < | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.66 | 0 | 1 | 1 |
| steatosis | 0.48 | $4.1 \cdot 10^{-10}$ | 20 | 20 |
| inflammation | 0.15 | 0.08 | 4571 | 4761 |
| fibrosis | 0.14 | 0.1 | 5283 | 5521 |
| NAFLD | 0.29 | 0.0003 | 713 | 758 |

- o glutamate receptor ligand-gated ion channel
- fast excitatory synaptic transmission in CNS
- key role in synaptic plasticity
- o association: GRID1 variants—increased risk of schizophrenia
- Protein not detected in liver (4 individuals, nextprot.org)



Glutamate receptor, metabotropic 8 GRM8, Obesity marker, non-metabolic




| Factor | r | p< | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.57 | $1.6 \cdot 10^{-15}$ | 3 | 3 |
| steatosis | 0.43 | $2.9 \cdot 10^{-8}$ | 56 | 61 |
| inflammation | 0.16 | 0.05 | 3387 | 3532 |
| fibrosis | 0.02 | 0.84 | 23864 | 24655 |
| NAFLD | 0.25 | 0.002 | 1253 | 1328 |

- o G-protein coupled receptor for glutamate
- o signaling inhibits adenylate cyclase activity
- o reported in brain

also: RAMP1, receptor (G protein-coupled) activity modifying protein 1 (negatively correlated)



Protein kinase C, ε, PRKCEObesity marker, non-metabolic




| Factor | r | p< | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.58 | $4.4 \cdot 10^{-16}$ | 2 | 2 |
| steatosis | 0.54 | $7.3 \cdot 10^{-13}$ | 3 | 3 |
| inflammation | 0.18 | 0.02 | 2254 | 2353 |
| fibrosis | 0.18 | 0.04 | 2988 | 3143 |
| NAFLD | 0.36 | $7.2 \cdot 10^{-6}$ | 263 | 283 |

- phospholipid- and DAG-dependent serine/threonine-protein kinase
- o wide range of functions
- o contributes HGF-induced cell migration
- regulation of multiple cellular processes linked to cytoskeletal proteins

also: CAMK1D, calcium/calmodulin-dependent protein kinase ID



Hydroxysteroid (17- β) dehydrogenase 7 HSD17B7, obesity markers, metabolic




| Factor | r | p< | rank metabolic | rank total |
|--------------|-------|----------------------|----------------|------------|
| obesity | 0.53 | $3.8 \cdot 10^{-13}$ | 1 | 11 |
| steatosis | 0.36 | $6.0 \cdot 10^{-6}$ | 20 | 297 |
| inflammation | -0.03 | 0.75 | 743 | 23041 |
| fibrosis | 0.07 | 0.44 | 532 | 15561 |
| NAFLD | 0.12 | 0.13 | 32 1 | 8303 |

- HSD17B7: 3-keto-steroid reductase (17-betahydroxysteroid dehydrogenase 7, estradiol 17-betadehydrogenase 7)
- o biosynthesis cholesterol, sex steroids also: Squalene epoxidase SQLE







| Factor | r | p < | rank metabolic | rank total |
|--------------|-------|----------------------|----------------|------------|
| obesity | -0.48 | $9.5 \cdot 10^{-11}$ | 3 | 41 |
| steatosis | -0.2 | 0.01 | 171 | 4210 |
| inflammation | 0.13 | 0.11 | 231 | 6346 |
| fibrosis | 0.06 | 0.49 | 568 | 16921 |
| NAFLD | 0.01 | 0.89 | 842 | 26148 |

- o rapid transport across the plasma membrane of many monocarboxylates
- o highest affinity for pyruvate
- o restricted expression in normal tissues, but widely expressed in cancer cells



Obesity markers

- Several receptors and signaling proteins correlate
 - Glutamate sensing increased
- o Genes of cholesterol synthesis
 - Lipoprotein turnover
- Monocarboxylate transport, anti-correlate
 - less cancerous hepatocytes



Outline


- o Introduction
- o Obesity markers
- o Steatosis markers
- o Inflammation markers
- o Fibrosis markers
- o General disease markers



Steatosis markers


| Gene | r | p< | rank non-metabolic | rank total | |
|----------|-------|----------------------|--------------------|------------|---|
| FABP4 | 0.63 | 0 | 1 | 1 | fatty acid binding protein 4, adipocyte |
| LPL | 0.56 | $9.8 \cdot 10^{-14}$ | 2 | 2 | lipoprotein lipase |
| PRKCE | 0.54 | $7.3 \cdot 10^{-13}$ | 3 | 3 | protein kinase C, epsilon |
| IGFBP2 | -0.53 | $1.6 \cdot 10^{-12}$ | 4 | 4 | insulin-like growth factor binding protein 2, 36kDa |
| | | $4.9 \cdot 10^{-12}$ | | 5 | calcium/calmodulin-dependent protein kinase ID |
| PRAMEF10 | | | | 8 | PRAME family member 10 |

| Gene | r | p< | rank metabolic | rank total | | |
|--------|-------|-----------------------|----------------|------------|--|--|
| ME1 | 0.48 | 6.1-10 ⁻¹⁰ | 1 | 21 | malic enzyme 1, NADP(+)-dependent, cytosolic | |
| COL1A1 | 0.45 | 5.2·10 ⁻⁹ | 2 | 39 | collagen, type I, alpha 1 | |
| ADSSL1 | 0.45 | 9.6·10 ⁻⁹ | 3 | 48 | adenylosuccinate synthase like 1 | |
| COL1A2 | 0.44 | $2.2 \cdot 10^{-8}$ | 4 | 56 | collagen, type I, alpha 2 | |
| GNMT | -0.44 | $2.2 \cdot 10^{-8}$ | 5 | 57 | glycine N-methyltransferase | |
| ABCB11 | -0.42 | $6.7 \cdot 10^{-8}$ | 6 | 78 | • | |










| Factor | r | p < | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.43 | $1.2 \cdot 10^{-8}$ | 115 | 122 |
| steatosis | 0.63 | 0 | 1 | 1 |
| inflammation | 0.37 | $3.8 \cdot 10^{-6}$ | 97 | 102 |
| fibrosis | 0.38 | $3.6 \cdot 10^{-6}$ | 155 | 174 |
| NAFLD | 0.57 | $2.2 \cdot 10^{-14}$ | 2 | 2 |

o lipid transport in adipocytes

Lipoprotein lipase, LIPL, steatosis marker, non-metabolic






| Factor | r | p< | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.32 | $3.0 \cdot 10^{-5}$ | 1135 | 1180 |
| steatosis | 0.56 | $9.8 \cdot 10^{-14}$ | 2 | 2 |
| inflammation | 0.24 | 0.003 | 857 | 896 |
| fibrosis | 0.24 | 0.01 | 1231 | 1309 |
| NAFLD | 0.43 | $4.1 \cdot 10^{-8}$ | 91 | 101 |

 expressed in heart, muscle, and adipose tissue (cells utilizing) VLDL

Malic enzyme 1, ME1, steatosis marker, metabolic






| Factor | r | p< | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.37 | $1.4 \cdot 10^{-6}$ | 24 | 506 |
| steatosis | 0.48 | $6.1 \cdot 10^{-10}$ | 1 | 21 |
| inflammation | 0.34 | $2.1 \cdot 10^{-5}$ | 8 | 173 |
| fibrosis | 0.38 | $3.2 \cdot 10^{-6}$ | 18 | 169 |
| NAFLD | 0.48 | $3.0 \cdot 10^{-10}$ | 4 | 37 |

o central metabolism enzyme, TCA








| Factor | r | p< | rank metabolic | rank total |
|--------------|------|---------------------|----------------|------------|
| obesity | 0.43 | $7.9 \cdot 10^{-9}$ | 7 | 111 |
| steatosis | 0.45 | $9.6 \cdot 10^{-9}$ | 3 | 48 |
| inflammation | 0.19 | 0.02 | 87 | 1953 |
| fibrosis | 0.13 | 0.12 | 260 | 6273 |
| NAFLD | 0.31 | $9.9 \cdot 10^{-5}$ | 34 | 593 |

o normally found in muscle cells







| Factor | r | p< | rank metabolic | rank total |
|--------------|-------|---------------------|----------------|------------|
| obesity | -0.27 | 0.0004 | 92 | 2393 |
| steatosis | -0.44 | $2.2 \cdot 10^{-8}$ | 5 | 57 |
| inflammation | -0.3 | 0.0002 | 17 | 414 |
| fibrosis | -0.37 | $6.8 \cdot 10^{-6}$ | 24 | 202 |
| NAFLD | -0.45 | $5.2 \cdot 10^{-9}$ | 6 | 65 |

- o methylgroups
- Ahrens et al.: NASH accompanied by higher DNA methylation content



Steatosis markers

- Dedifferentiation
 - several genes noted in adipocytes
 - enzymes normally found in adipocytes, myocytes
- Methyl group supply
 - glycine methyltransferase
- o Proteins extracellular matrix
 - Col1a1 Col1a2




Outline

- o Introduction
- o Obesity markers
- Steatosis markers
- o Inflammation markers
- o Fibrosis markers
- o General disease markers








o qualitative parameter, lower r








| Factor | r | p< | rank metabolic | rank total |
|--------------|------|----------------------|----------------|--------------|
| obesity | 0.28 | 0.0004 | 2219 | 23 10 |
| steatosis | 0.4 | $3.8 \cdot 10^{-7}$ | 127 | 137 |
| inflammation | 0.54 | $1.3 \cdot 10^{-12}$ | 1 | 1 |
| fibrosis | 0.17 | 0.04 | 3317 | 3482 |
| NAFLD | 0.48 | $3.0 \cdot 10^{-10}$ | 35 | 39 |

- o gelatinase B, 92kDa, type IV, collagenase
- o degrades extracellular matrix

Ubiquitin D, UBD, inflammation marker, non-metabolic






| Factor | r | p < | rank metabolic | rank total |
|--------------|-------|----------------------|----------------|------------|
| obesity | -0.13 | 0.1 | 11683 | 12095 |
| steatosis | 0.13 | 0.1 | 9477 | 9829 |
| inflammation | 0.52 | $1.4 \cdot 10^{-11}$ | 2 | 2 |
| fibrosis | 0.42 | $2.5 \cdot 10^{-7}$ | 90 | 99 |
| NAFLD | 0.47 | $1.5 \cdot 10^{-9}$ | 45 | 49 |

o attachement leads to rapid 26S proteasome degradation

Plexin C1, PLXNC1, inflammation marker, non-metabolic






| Factor | r | p < | ${\bf rank\ metabolic}$ | rank total |
|--------------|------|----------------------|-------------------------|------------|
| obesity | 0.13 | 0.09 | 11224 | 11624 |
| steatosis | 0.29 | 0.0004 | 1080 | 1144 |
| inflammation | 0.5 | $4.9 \cdot 10^{-11}$ | 3 | 3 |
| fibrosis | 0.32 | $9.8 \cdot 10^{-5}$ | 358 | 392 |
| NAFLD | 0.47 | $1.2 \cdot 10^{-9}$ | 41 | 45 |

- o receptor for SEMA7A, herpesvirus Sema protein, etc.
- o binding triggers secretion of IL6 and IL8.
- o rearrangement of the cytoskeleton

Thymidylate synthetase, TYMS, inflammation marker, metabolic






| Factor | r | p < | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.09 | 0.23 | 532 | 16116 |
| steatosis | 0.25 | 0.002 | 94 | 2031 |
| inflammation | 0.46 | $4.1 \cdot 10^{-9}$ | 1 | 12 |
| fibrosis | 0.41 | $6.2 \cdot 10^{-7}$ | 12 | 120 |
| NAFLD | 0.49 | $1.0 \cdot 10^{-10}$ | 2 | 27 |

o DNA replication and repair

Ficolin 1, FCN1, inflammation marker, metabolic






| Factor | r | p< | ${\bf rank\ metabolic}$ | rank total |
|--------------|------|---------------------|-------------------------|------------|
| obesity | 0.05 | 0.55 | 715 | 21898 |
| steatosis | 0.16 | 0.04 | 266 | 6987 |
| inflammation | 0.44 | $1.2 \cdot 10^{-8}$ | 2 | 19 |
| fibrosis | 0.21 | 0.01 | 110 | 1872 |
| NAFLD | 0.35 | $1.1 \cdot 10^{-5}$ | 21 | 307 |

- o collagen/fibrinogen domain containing
- o expressed in leukocytes
- o plasma protein
- o elastin binding

TGFβ-induced 68kDa protein, TGFBI, inflammation marker, metabolic





| Factor | г | p< | rank metabolic | rank total |
|--------------|-------|---------------------|----------------|------------|
| obesity | -0.07 | 0.35 | 610 | 18591 |
| steatosis | 0.21 | 0.01 | 159 | 3829 |
| inflammation | 0.42 | $6.5 \cdot 10^{-8}$ | 3 | 31 |
| fibrosis | 0.35 | $2.3 \cdot 10^{-5}$ | 27 | 282 |
| NAFLD | 0.43 | $3.8 \cdot 10^{-8}$ | 10 | 99 |

- o adhesion protein
- o binds type I, II, IV collagens
- o cartilage: endochondral bone formation



Inflammation marker

- Secreting interleukins
 - plexin C1: IL6 IL8 secretion
- o Tissue reorganization
 - Protein degradation
 - Cellular polarization/migration
 - o cadherin 1
 - Ficolin 1, plasma protein
 - Adhesion protein, TGFBI
- o DNA replication
 - thymidylate synthase



Outline

- o Introduction
- o Obesity markers
- Steatosis markers
- o Inflammation markers
- o Fibrosis markers
- o General disease markers




Fibrosis markers

| Gene | r | p< | rank non-metabolic | rank total | |
|-------|------|-----------------------|--------------------|------------|---|
| STMN2 | 0.66 | 0 | 1 | 1 | stathmin-like 2 |
| THY1 | 0.58 | $4.8 \cdot 10^{-14}$ | 2 | 2 | Thy-1 cell surface antigen |
| DKK3 | 0.57 | $2.2 \cdot 10^{-13}$ | 3 | 3 | dickkopf WNT signaling pathway inhibitor 3 |
| CFTR | 0.56 | 5.6·10 ⁻¹³ | 4 | 4 | cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) |
| AEBP1 | 0.56 | $1.1 \cdot 10^{-12}$ | 5 | 5 | AE binding protein 1 |
| NFASC | 0.53 | $1.4 \cdot 10^{-11}$ | 6 | | neurofascin |


| Gene | r | p< | rank metabolic | rank total | |
|--------|------|-----------------------|----------------|------------|---|
| | | $7.0 \cdot 10^{-12}$ | | 6 | collagen, type (, alpha 2 |
| | | $3.3 \cdot 10^{-10}$ | | 23 | collagen, type I, alpha 1 |
| ABCC4 | 0.49 | 8.1·10 ⁻¹⁰ | 3 | 25 | ATP-binding cassette, sub-family C (CFTR/MRP), member 4 |
| COL4A2 | 0.49 | 1.3·10 ⁻⁹ | 4 | | collagen, type IV, alpha 2 |
| CA12 | 0.47 | 4.6·10 ⁻⁹ | 5 | 41 | carbonic anhydrase XII |
| COL3A1 | 0.46 | 1.2.10-8 | 6 | 52 | collagen, type III, alpha 1 |

o high **r** despite qualitative



Stathmin-like 2, STMN2, fibrosis marker, non-metabolic






| Factor | r | p< | ${\bf rank\ metabolic}$ | rank total |
|--------------|-------|----------------------|-------------------------|------------|
| obesity | -0.04 | 0.59 | 21733 | 22459 |
| steatosis | 0.29 | 0.0004 | 1088 | 1152 |
| inflammation | 0.43 | $4.9 \cdot 10^{-8}$ | 27 | 29 |
| fibrosis | 0.66 | 0 | 1 | 1 |
| NAFLD | 0.58 | $9.1 \cdot 10^{-15}$ | 1 | 1 |

- o Superior cervical ganglion-10
- o neuronal growth-associated protein
 - regulator of microtubule stability
- o involved in osteogenesis








| Factor | r | p< | rank metabolic | rank total |
|--------------|-------|----------------------|----------------|------------|
| obesity | -0.02 | 0.81 | 24740 | 25570 |
| steatosis | 0.33 | $3.5 \cdot 10^{-5}$ | 474 | 504 |
| inflammation | 0.42 | $1.0 \cdot 10^{-7}$ | 31 | 34 |
| fibrosis | 0.58 | $4.8 \cdot 10^{-14}$ | 2 | 2 |
| NAFLD | 0.55 | $1.6 \cdot 10^{-13}$ | 4 | 4 |

o cell-cell or cell-ligand interactions during synaptogenesis








| Factor | r | p< | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.04 | 0.62 | 22204 | 22942 |
| steatosis | 0.28 | 0.0004 | 1127 | 1191 |
| inflammation | 0.21 | 0.01 | 1529 | 1606 |
| fibrosis | 0.57 | $2.2 \cdot 10^{-13}$ | 3 | 3 |
| NAFLD | 0.41 | $1.3 \cdot 10^{-7}$ | 118 | 131 |

- Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt
- o Dkks implicated in
 - adult bone formation
 - bone disease
 - cancer
 - Alzheimer disease







| Factor | r | p < | ${\bf rank\ metabolic}$ | rank total |
|--------------|------|----------------------|-------------------------|------------|
| obesity | 0.16 | 0.04 | 326 | 8932 |
| steatosis | 0.44 | $2.2 \cdot 10^{-8}$ | 4 | 56 |
| inflammation | 0.27 | 0.001 | 23 | 576 |
| fibrosis | 0.54 | $7.0 \cdot 10^{-12}$ | 1 | 6 |
| NAFLD | 0.49 | $1.8 \cdot 10^{-10}$ | 3 | 31 |

- o component of the extracellular matrix
- o mostly found in skin, tendon, bone



Fibrosis markers

- o Tissue modeling
 - STMN2, Superior cervical ganglion10, microtubule stability
 - Thy1 cell surface antigen
 - Collagen: Col1a2, 1a1,4a2,3a1
 - Bone formation: STMN2, DKK3
- o Loss of liver organization
 - DKK3, antagonist of Wnt signaling



Outline


- o Introduction
- o Obesity markers
- Steatosis markers
- o Inflammation markers
- o Fibrosis markers
- o General disease markers






| Gene | r | p< | rank non-metabolic | rank total | |
|---------|-------|-------------------------------|--------------------|------------|--|
| STMN2 | 0.58 | 9.1.10-15 | 1 | 1 | stathmin-like 2 |
| FABP4 | 0.57 | $2.2 \cdot 10^{-14}$ | 2 | 2 | fatty acid binding protein 4, adipocyte |
| SPP1 | 0.57 | $3.1 \cdot 10^{-14}$ | 3 | 3 | secreted phosphoprotein 1 |
| THY1 | 0.55 | $1.6 \cdot 10^{-13}$ | 4 | 4 | Thy-1 cell surface antigen |
| FAT1 | 0.54 | $8.2 \cdot 10^{-13}$ | 5 | 5 | FAT atypical cadherin 1 |
| DNAJC12 | -0.53 | 2 .1·10 ⁻¹² | 6 | 6 | DnaJ (Hsp40) homolog, subfamily C, member 12 |

| Gene | r | p< | rank metabolic | rank total | |
|--------|-------|-----------------------|----------------|------------|--|
| COL1A1 | 0.53 | 3.2·10 ⁻¹² | 1 | 8 | collagen, type I, alpha 1 |
| TYMS | 0.49 | $1.0 \cdot 10^{-10}$ | 2 | 27 | thymidylate synthetase |
| COL1A2 | 0.49 | $1.8 \cdot 10^{-10}$ | 3 | 31 | collagen, type I, alpha 2 |
| ME1 | 0.48 | $3.0 \cdot 10^{-10}$ | 4 | 37 | malic enzyme 1, NADP(+)-dependent, cytosolic |
| COL4A2 | 0.46 | $3.6 \cdot 10^{-9}$ | 5 | 58 | collagen, type IV, alpha 2 |
| GNMT | -0.45 | 5.2·10 ⁻⁹ | 6 | 65 | glycine N-methyltransferase |










| Factor | r | p< | ${\bf rank\ metabolic}$ | rank total |
|--------------|------|----------------------|-------------------------|------------|
| obesity | 0.11 | 0.17 | 13971 | 14452 |
| steatosis | 0.42 | $6.2 \cdot 10^{-8}$ | 70 | 75 |
| inflammation | 0.45 | $8.7 \cdot 10^{-9}$ | 15 | 16 |
| fibrosis | 0.46 | $9.1 \cdot 10^{-9}$ | 43 | 48 |
| NAFLD | 0.57 | $3.1 \cdot 10^{-14}$ | 3 | 3 |

- o Osteopontin/Immunoglobulin Alpha 1
- o attachment of osteoclasts to the mineralized bone matrix
- o binds hydroxyapatite
- o cytokine that up-regulates expression of interferon-γ and IL-12.

Collagen, type I, alpha 1, COL1A1, NAFLD progression marker, metabolic





| Factor | r | p < | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.12 | 0.12 | 434 | 12828 |
| steatosis | 0.45 | $5.2 \cdot 10^{-9}$ | 2 | 39 |
| inflammation | 0.33 | $4.5 \cdot 10^{-5}$ | 9 | 246 |
| fibrosis | 0.5 | $3.3 \cdot 10^{-10}$ | 2 | 23 |
| NAFLD | 0.53 | $3.2 \cdot 10^{-12}$ | 1 | 8 |

o main component of the extracellular matrix



General disease markers

- o Tissue remodelling
 - Osteoporin SPP1, osteoclast attachment
- o Extracellular matrix
 - Col1a1



Outlook

- Finer classification of proteins
 - receptor/enzyme/transporter/structural/signaling/secretion
- o Experimental validation
 - layer of protein
 - secretion products
 - secondary products (plexin → IL6,IL8)
 - macroscopic



Take-home message

- o Obesity markers
 - glutamate sensing
 - cholesterol
- Steatosis markers
 - "hepatocytes become adipocytes"
 - methylation
- o Inflammation markers
 - Tissue reorganization
 - DNA replication
- o Fibrosis markers
 - Loss of liver organization
 - "liver becomes bone"
- o General disease markers
 - Osteoporin & Collagen 1a1






Acknowledgements

- Hermann-Georg Holzhütter
 - Biochemie, Charité
- o Jochen Hampe
 - Dresden/Kiel





Squalene epoxidase SQLE Obesity marker, metabolic




| Factor | r | p< | rank metabolic | rank total |
|--------------|------|----------------------|----------------|------------|
| obesity | 0.5 | $8.5 \cdot 10^{-12}$ | 2 | 21 |
| steatosis | 0.39 | $7.8 \cdot 10^{-7}$ | 12 | 160 |
| inflammation | 0.12 | 0.14 | 254 | 7330 |
| fibrosis | 0.13 | 0.14 | 280 | 6920 |
| NAFLD | 0.24 | 0.003 | 91 | 1490 |

o cholesterol synthesis








| Factor | r | p< | rank metabolic | rank total |
|--------------|------|---------------------|----------------|------------|
| obesity | 0.17 | 0.03 | 291 | 7908 |
| steatosis | 0.3 | 0.0001 | 48 | 830 |
| inflammation | 0.38 | $1.4 \cdot 10^{-6}$ | 4 | 72 |
| fibrosis | 0.37 | $7.4 \cdot 10^{-6}$ | 25 | 205 |
| NAFLD | 0.43 | $3.6 \cdot 10^{-8}$ | 9 | 96 |

- o Mental Retardation, X-Linked 63.
- o synthesis of cellular lipids
- o degradation via beta-oxidation.
- Preferentially uses arachidonate and eicosapentaenoate







| Factor | r | p< | rank metabolic | rank total |
|--------------|-------|----------------------|----------------|------------|
| obesity | -0.01 | 0.94 | 878 | 27290 |
| steatosis | 0.16 | 0.05 | 281 | 7420 |
| inflammation | 0.37 | $2.7 \cdot 10^{-6}$ | 5 | 86 |
| fibrosis | 0.49 | $8.1 \cdot 10^{-10}$ | 3 | 25 |
| NAFLD | 0.42 | $5.4 \cdot 10^{-8}$ | 13 | 108 |

- MRP/CMOAT-Related ABC Transporter
- o organic anion pump
- o relevant to cellular detoxification.